EADV 2026: Key vitiligo highlights
Systemic treatment and phase 3 vitiligo data from EADV 2026
Review key advances in non-segmental vitiligo presented at the 35th European Academy of Dermatology and Venereology Congress (EADV 2026). Gain insights into emerging systemic treatment strategies and patient selection for systemic therapy, and hear Iltefat Hamzavi (Henry Ford Hospital, Detroit, Michigan, USA) discuss findings from the phase 3 Tranquillo clinical program.
Key topics include:
- The evolving role of oral Janus kinase (JAK) inhibitors in non-segmental vitiligo
- Defining disease severity and identifying candidates for systemic treatment
- Phase 3 efficacy and safety findings from the Tranquillo clinical program
- Disease stabilization as an emerging treatment goal in vitiligo
- Remaining unmet needs and future directions in vitiligo care
Tranquillo insights with Iltefat Hamzavi
Watch Iltefat Hamzavi discuss phase 3 Tranquillo findings, disease stabilization, and systemic treatment in vitiligo.
EADV 2026: Systemic treatment in vitiligo
Review systemic therapies and phase 3 Tranquillo efficacy and safety findings in non-segmental vitiligo from EADV 2026.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.